Literature DB >> 17279

Effects of tilorone hydrochloride on experimental flavivirus infections in mice.

V V Vargin, W Zschiesche, B F Semenov.   

Abstract

The effect of tilorone hydrochloride on experimental infections of mice with West Nile, Langat and Dengue type 2 viruses were studied. The drug significantly reduced the mortality after intraperitoneal inoculation of West Nile virus, but failed to affect intracerebral infection with Langat or Dengue viruses. Tilorone partially reversed cyclophosphan-enhanced mortality after extraneural inoculation of West Nile and Langat viruses. The possible modes of action of tilorone, interferon-inducing ability and stimulation of humoral immunity, are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 17279

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  5 in total

Review 1.  The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response.

Authors:  Bradley S Schneider; Stephen Higgs
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-03-14       Impact factor: 2.184

2.  Aedes aegypti saliva alters leukocyte recruitment and cytokine signaling by antigen-presenting cells during West Nile virus infection.

Authors:  Bradley S Schneider; Lynn Soong; Lark L Coffey; Heather L Stevenson; Charles E McGee; Stephen Higgs
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

3.  Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses.

Authors:  Sean Ekins; Peter B Madrid
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

4.  Tilorone-Dihydrochloride Protects against Rift Valley Fever Virus Infection and Disease in the Mouse Model.

Authors:  Kendra N Johnson; Birte Kalveram; Jennifer K Smith; Lihong Zhang; Terry Juelich; Colm Atkins; Tetsuro Ikegami; Alexander N Freiberg
Journal:  Microorganisms       Date:  2021-12-31

5.  Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.

Authors:  Sean Ekins; Thomas R Lane; Peter B Madrid
Journal:  Pharm Res       Date:  2020-03-25       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.